NCT04280965

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

Quetiapine Augmentation of Prolonged Exposure (PE) Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for veterans considering prolonged exposure (PE) therapy, following the model established by Foa et al, we need to establish safety, and feasibility of quetiapine compared to treatment as usual (TAU) which employs multiple medications commonly used for PTSD in the VA system.

Conditions

• Post Traumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	Quetiapine Fumarate	Atypical antipsychotic
OTHER	Standard of care meducations	SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine

Timeline

• Start date: 2019-02-01
• Primary completion: 2022-04-29
• Completion: 2022-10-17
• First posted: 2020-02-21
• Last updated: 2023-05-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study